Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.5787
-0.0162 (-2.72%)
Jan 28, 2026, 4:00 PM EST - Market closed
Femasys Revenue
Femasys had revenue of $729.39K in the quarter ending September 30, 2025, with 31.44% growth. This brings the company's revenue in the last twelve months to $2.06M, up 63.53% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$2.06M
Revenue Growth
+63.53%
P/S Ratio
8.52
Revenue / Employee
$29,035
Employees
71
Market Cap
34.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.63M | 557.14K | 51.97% |
| Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
| Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
| Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
| Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
| Dec 31, 2019 | 929.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 87.37M |
| Retractable Technologies | 37.90M |
| Bionano Genomics | 28.72M |
| Jin Medical International | 22.83M |
| Precision Optics Corporation | 21.58M |
| Nephros | 17.93M |
| Ekso Bionics Holdings | 14.75M |
| Milestone Scientific | 8.93M |
FEMY News
- 15 days ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 5 weeks ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 2 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 3 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 3 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 4 months ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 5 months ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 5 months ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire